	Application No.	Applicant(a)
	Application No.	Applicant(s)
Notice of Allowability	10/614,460	WOLFF ET AL. Art Unit
Notice of Anonability	Examiner	Art Onit
	Konata M. George	1616
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>TD filed June 25, 2004</u> .		
2. The allowed claim(s) is/are <u>1-30</u> .		
3. The drawings filed on are accepted by the Examiner.		
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 		
· ——		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) \square including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t	.84(c)) should be written on the drawing he header according to 37 CFR 1.121(c	ngs in the front (not the back) of d).
7. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT		
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0	Paper No./Mail Dat 08), 7. ☐ Examiner's Amendr	
Paper No./Mail Date	<u> </u>	
4. Examiner's Comment Regarding Requirement for Deposit		ent of Reasons for Allowance
of Biological Material	9. Other	

Application/Control Number: 10/614,460 Page 2

Art Unit: 1616

DETAILED ACTION

Claims 1-30 are pending in this application.

Action Summary

- 1. The rejection of claim 1 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 6 of copending application 10/382,266 is hereby withdrawn.
- 2. The rejection of claims 1-9 and 13-30 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 2 of U.S. Patent No. 6,303,607 B1 is hereby withdrawn, as a terminal disclaimer was timely filed.
- 3. The rejection of claims 1-7 and 18-30 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 6,479,496 B1 is hereby withdrawn, as a terminal disclaimer was timely filed.
- 4. The rejection of claims 1-9 and 13-30 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-12 of U.S. Patent No. 6,525,057 B2 is hereby withdrawn, as a terminal disclaimer was timely filed.
- 5. The rejection of claims 1-7 and 20-30 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-27 of U.S. Patent No. 6,620,814 B2 is hereby withdrawn, as a terminal disclaimer was timely filed.

Statement of Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

The claims are allowable over the cited prior art because the prior art does not teach, disclose nor make obvious a method for treating chronic angina by administering a sustained release pharmaceutical dosage of at least 50% by weight of ranolazine in no more than two tablets per dose. The closet prior art is that of the inventor. U.S. Patents 6,303,607 B1, 6,479,496 B1, 6,525,057 B2 and 6,620,814 B2 all teach treating angina by administering a pharmaceutical of ranolazine.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

6. Claims 1-30 are allowed.

Telephone Inquiries

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konata M. George, whose telephone number is (571) 272-0613. The examiner can normally be reached from 8AM to 5:30PM Monday to Thursday, and on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached at (571) 272-0887. The fax phone numbers for

Application/Control Number: 10/614,460

Art Unit: 1616

Page 4

the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Konata M. George

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600